Information Provided By:
Fly News Breaks for January 13, 2020
ACST, AZN, AMRN
Jan 13, 2020 | 10:56 EDT
Roth Capital analyst Yasmeen Rahimi maintained a Buy rating and $31 price target on Amarin (AMRN) following the failures of two competitors to Amarin's Vascepa -- those being the discontinuation of AstraZeneca's (AZN) Epanova trial and the negative TRIOLOGY 1 data from Acasti Pharma's (ACST) CaPre -- which leaves Vascepa as the "'go-to' omega-3 product" and kills the central bear case against Amarin.